Compass Therapeutics Inc. (CMPX) — Cash Flow-to-Debt Ratio
Compass Therapeutics Inc. (CMPX) has a Cash Flow-to-Debt Ratio of -0.50x as of September 2025, meaning its operating cash flow of $-10.85 Million could theoretically repay -1% of its total liabilities ($21.65 Million) in one year. See CMPX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Compass Therapeutics Inc. Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Compass Therapeutics Inc. across 7 annual periods. Also explore Compass Therapeutics Inc. (CMPX) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Compass Therapeutics Inc. (2018–2024)
Year-by-year debt coverage analysis for Compass Therapeutics Inc.. For market capitalisation and broader financial context, see Compass Therapeutics Inc. market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.96x | $-44.85 Million | $15.17 Million | ▲ +39.3% |
| 2023 | -4.87x | $-40.62 Million | $8.34 Million | ▼ -157.1% |
| 2022 | -1.90x | $-34.12 Million | $18.01 Million | ▼ -31.8% |
| 2021 | -1.44x | $-19.67 Million | $13.68 Million | ▲ +35.8% |
| 2020 | -2.24x | $-26.80 Million | $11.97 Million | ▼ -951.4% |
| 2019 | -0.21x | $-31.74 Million | $148.98 Million | ▲ +5.5% |
| 2018 | -0.23x | $-33.68 Million | $149.40 Million | — |